U092 - Warts
Monday, February 19; 4:30 PM - 5:30 PM
Following this course, the attendee should be able to:
- Recognize clinical manifestations of human papillomaviruses.
- Recognize the oncogenic potential of certain human papillomaviruses.
- Discuss current therapies for and preventions against human papillomaviruses.
This session will cover the clinical manifestations of human papillomaviruses (HPV) as well as laboratory tests that will confirm the presence and type of HPV. The oncogenic potential of certain HPV types will be discussed, including co-factors that may contribute to cancer development. The available therapies for HPV will be covered and will include antiviral and immunomodulatory treatments. Prevention strategies will be discussed and will include nine-valent, quadrivalent and bivalent vaccines.
- Silverberg, Nanette Blythe, MD: Johnson & Johnson Consumer Products Company – C(H); Pfizer Inc. – Speaker/Faculty Education(H); Pierre Fabre Dermatologie – A(H); Regeneron – A(H); Valeant Pharmaceuticals International – A(H);